Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBI3 siRNA
- Development stage
- Preclinical
- Lead developer
- Shiga University of Medical Science
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
EBI3 siRNA is a small interfering RNA therapeutic candidate designed to silence the expression of the Epstein-Barr virus-induced gene 3 (EBI3). EBI3 encodes a secretory glycoprotein that is significantly upregulated in various lung cancers, including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer. Research indicates that EBI3 acts as an oncoprotein, and its overexpression is linked to poor patient prognosis. By utilizing the RNA interference (RNAi) pathway, EBI3 siRNA targets and degrades EBI3 mRNA, leading to the suppression of cancer cell proliferation and growth. This approach has been explored by researchers at the Shiga University of Medical Science and the University of Tokyo as a potential precision medicine strategy for lung cancer.
- Other names
- Epstein-Barr virus-induced gene 3 siRNAsiRNA against EBI3
02
Targets
IL (Interleukins)
Beyond the preview
Go deeper on EBI3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBI3 siRNA.